These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34274223)

  • 41. Stereotactic body radiation therapy with hydrogel spacer: a salvage reirradiation strategy for prostate cancer recurrence.
    Fiorentino A; Giaj Levra N; Mazzola R; Fersino S; Ricchetti F; Ballario R; Ruggieri R; Alongi F
    Minerva Urol Nefrol; 2016 Oct; 68(5):464-6. PubMed ID: 27643656
    [No Abstract]   [Full Text] [Related]  

  • 42. Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?
    Roy S; Morgan SC
    Curr Urol Rep; 2019 Jul; 20(9):53. PubMed ID: 31359187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erectile function after stereotactic body radiotherapy for localized prostate cancer.
    Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE
    BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
    Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
    Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of radiotherapy for high risk localized prostate cancers.
    Hennequin C; Labidi M; Quéro L
    Cancer Radiother; 2021 Oct; 25(6-7):660-662. PubMed ID: 34417087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol.
    Pasquier D; Le Deley MC; Tresch E; Cormier L; Duterque M; Nenan S; Lartigau E
    BMJ Open; 2019 Aug; 9(8):e026666. PubMed ID: 31377694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy.
    Yamazaki H; Nakamura S; Suzuki G; Yoshida K; Yoshioka Y; Koizumi M; Ogawa K
    Anticancer Res; 2015 Oct; 35(10):5167-77. PubMed ID: 26408674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
    Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
    Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
    Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
    Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
    Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
    Kim HJ; Phak JH; Kim WC
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed.
    Detti B; Bonomo P; Masi L; Doro R; Cipressi S; Iermano C; Bonucci I; Franceschini D; Di Brina L; Baki M; Simontacchi G; Meattini I; Carini M; Serni S; Nicita G; Livi L
    World J Urol; 2016 Mar; 34(3):311-7. PubMed ID: 26062525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.
    Beckta JM; Nosrati JD; Yu JB
    Urol Oncol; 2019 Sep; 37(9):619-627. PubMed ID: 30738746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Radiotherapy for patients with early-stage glottic squamous cell carcinoma of the larynx: Interest of hypofractionation?].
    Tonneau M; Matta R; Lals S; Mirabel X; Crop F; Lacornerie T; Pasquier D; Escande A; Liem X
    Cancer Radiother; 2021 Dec; 25(8):801-810. PubMed ID: 33931299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hypofractionated irradiation of prostate cancer: What is the radiobiological understanding in 2017?].
    Cosset JM
    Cancer Radiother; 2017 Oct; 21(6-7):447-453. PubMed ID: 28847464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypofractionated Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Tumours in Children and Young Adults.
    Chandy E; Taylor H; Gaito S; Wells E; Jones C; Meehan C; Burland H; Stone J; Snowball C; Mashru J; Riddell C; Hon Y; Welsh L; Saran F; Mandeville H
    Clin Oncol (R Coll Radiol); 2020 May; 32(5):316-326. PubMed ID: 31813663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
    Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
    Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.